RCT | Lurbinectedin plus Doxorubicin are no better than physician’s choice of chemotherapy in relapsed small-cell lung cancer.
20 Oct, 2022 | 12:19h | UTCCombination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Lurbinectedin + doxorubicin did not improve overall survival vs control in relapsed SCLC., but did show a favourable haematological safety profile
ATLANTIS trial from Prof Luis Paz-Ares & colleagues https://t.co/oF57GJx7u1 pic.twitter.com/8aoqTqXUl7
— The Lancet Respiratory Medicine (@LancetRespirMed) October 17, 2022